戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lestatic liver tests and the highly specific antimitochondrial antibody.
2 cholangitis, with typical seroreactivity for antimitochondrial antibodies.
3 er in Dsg3(-/-) KCs nor due to absorption of antimitochondrial antibodies.
4  autoantigen reservoir and the production of antimitochondrial antibodies.
5 hallmark of primary biliary cirrhosis is the antimitochondrial antibody, a highly disease-specific an
6                              The presence of antimitochondrial antibodies (AMA) is a serological feat
7 pathogenic anti-desmoglein (Dsg) 3 +/- 1 and antimitochondrial antibodies (AMA), but it remained unkn
8 titated B-cell levels in all mice as well as antimitochondrial antibodies (AMA), serum and hepatic le
9 ehydrogenase complex (PDC) are the target of antimitochondrial antibodies (AMA).
10 nt with primary biliary cirrhosis (PBC) lack antimitochondrial antibodies (AMA).
11  muscle acidosis with exercise linked to the antimitochondrial antibody (AMA) diagnostic of the disea
12 of anti-BCOADC E2 positive (1/3), and 12% of antimitochondrial antibody (AMA) negative patients with
13 re evaluated for association with PBC and/or antimitochondrial antibody (AMA) positivity with logisti
14                           The immunodominant antimitochondrial antibody (AMA) response in primary bil
15 li in susceptible hosts is the basis for the antimitochondrial antibody (AMA) response.
16  evaluated for association with PBC and with antimitochondrial antibody (AMA) status and prior orthot
17 h PBC with respect to ethnicity, gender, and antimitochondrial antibody (AMA) status; 73 of 535 (13.6
18 f 29 patients who were positive in serum for antimitochondrial antibody (AMA), the disease-specific m
19 ntibodies were detected in 81% (79 of 97) of antimitochondrial antibody (AMA)-positive patients with
20                         We hypothesized that antimitochondrial antibodies (AMAs) and development of a
21 n primary biliary cirrhosis (PBC), including antimitochondrial antibodies (AMAs) and extensive portal
22                                              Antimitochondrial antibodies (AMAs) directed against the
23  the prevalence and unusually high levels of antimitochondrial antibodies (AMAs) in patients with PBC
24 cholestasis, and test positive (>or=90%) for antimitochondrial antibodies (AMAs) in serum.
25                             The detection of antimitochondrial antibodies (AMAs) is an important crit
26                                  Originally, antimitochondrial antibodies (AMAs) were detected by ind
27 aracteristics, and outcomes of patients with antimitochondrial antibodies (AMAs), but no clinical evi
28  biliary cirrhosis (PBC) is characterized by antimitochondrial antibodies (AMAs), directed to the E2
29 is (PBC) characteristically show circulating antimitochondrial antibodies (AMAs), liver-infiltrating
30 eity of patients and the classic hallmark of antimitochondrial antibodies (AMAs).
31 y of liver immunopathology and appearance of antimitochondrial antibodies (AMAs).
32 te dehydrogenase complex E2 subunit (PDC-E2) antimitochondrial antibodies (AMAs).
33 d the prototypic serologic response includes antimitochondrial antibodies (AMAs).
34 genase complex and subsequent development of antimitochondrial antibodies and autoreactive T cells.
35 s (PBC) are characterized by the presence of antimitochondrial antibodies and elevated levels of immu
36 estricted to T cells (dnTGF-betaRII) develop antimitochondrial antibodies and liver inflammation simi
37 ver disease characterized by the presence of antimitochondrial antibodies and the destruction of smal
38 e diagnosis relies on the detection of serum antimitochondrial antibodies directed against a complex
39                                          The antimitochondrial antibodies from different PV patients
40                                  Presence of antimitochondrial antibody in serum is almost diagnostic
41 ) is sometimes diagnosed based on a positive antimitochondrial antibody in the appropriate clinical s
42                  The downstream signaling of antimitochondrial antibodies involved JNK and late p38 M
43  IL-6(-/-)) and examined for the presence of antimitochondrial antibodies, levels of cytokines, histo
44 ment regimen of 10 consecutive patients with antimitochondrial antibody-positive PBC who had an incom
45  of liver biochemical tests in patients with antimitochondrial antibody-positive PBC who responded in
46  any two of three diagnostic criteria (i.e., antimitochondrial antibody-positive titer >/=1 in 40, ch
47                           The immunodominant antimitochondrial antibody response in patients with pri
48 ductopenia associated with the production of antimitochondrial antibodies that react with a protein a
49             The serologic hallmark of PBC is antimitochondrial antibodies that react with the pyruvat
50 made using evidence of cholestasis, positive antimitochondrial antibody titers and liver biopsy findi
51 id not serve as a surrogate antigen allowing antimitochondrial antibodies to enter KCs.
52                                              Antimitochondrial antibodies were pathogenic because the
53                 In addition, antinuclear and antimitochondrial antibodies were present in serum 3 yea